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Abstract 
Patients with diabetes mellitus (DM) are likely to develop many types of infections, which affect the transport of glucose into 
tissues. Diabetes increases the susceptibility to different kinds of respiratory infections, is often identified as an independent risk 
factor for developing lower respiratory tract infections. Pulmonary infections caused by Mycobacterium tuberculosis, Staphylococ-
cus aureus, gram-negative bacteria and fungi may occur with an increased frequency, whereas infections due to Streptococcus 
pneumonia or influenza virus may be associated with increased morbidity and mortality. During lung infection, there are changes 
in the local and ciliary epithelial lining. Increased susceptibility to pneumococcal infection by people with diabetes is the result of 
reduced defense capability of antibodies to protein antigens. The relationship between diabetes and pulmonary tuberculosis is well 
known, and the incidence of tuberculosis in diabetic individuals is 4−5 times greater than among the non-diabetic population. It is 
thought that malfunction of monocytes in patients with diabetes may contribute to the increased susceptibility to tuberculosis and/
or a worse prognosis. Hospitalization of patients with diabetes due to influenza virus or flu-like infections is up to 6 times more likely 
to occur compared to healthy individuals, also diabetic patients are more likely to be hospitalized due to infection complications. Im-
munization with influenza and anti-pneumococcal vaccines is recommended to reduce hospitalizations, deaths, and medical expen-
ses. Diabetes, especially the uncontrolled one, predisposes to fungal infection, the most common candidiasis and mucormycosis. 
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Introduction
Lower respiratory tract infections (LRTI) are 
the most common diseases in the world [1]. In the 
United States, the incidence of lower respiratory 
tract infections and associated mortality rate are 
higher than of other infectious diseases. According 
to the WHO report, LRTI accounted for 6.9% of all 
deaths in 2002 [2]. High rates of lower respiratory 
tract infections contributed to the development of 
guidelines for the diagnosis and treatment of lower 
respiratory tract infections by European countries 
and the USA. These guidelines are subject to regu-
lar evaluation, which is based on review of multiple 
medical and epidemiological studies. The Ameri-
can Thoracic Society (ATS), the Infectious Diseases 
Society of America (IDSA) and the British Thoracic 
Society (BTS) presented comprehensive guidelines 
[3]. Some of the most common respiratory tract 
infections in diabetics includes: acute bronchitis, 
sinusitis, otitis media, pneumonia. Etiological 
factors are bacterial, viral and fungal. Respiratory 
tract infections are the cause of increased hospita-
lizations in diabetic individuals compared to those 
without diabetes [4−6].
Immunodeficiency in diabetes
The complement system is one of the main 
mechanisms of humoral immunity. It contains 
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plasma proteins and cell surface proteins whose 
main functions are to promote opsonization and 
phagocytosis of microorganisms by macrophages 
and neutrophils and induction of lysis of micro-
organisms. Induction of the complement system 
mediates a B cell antibody production. Lowering 
the content of C4 in patients with DM may be 
associated with dysfunctional neutrophils and 
decreased response to cytokines. Mononucle-
ar cells and monocytes of DM patients release 
lower amounts of interleukin-1 (IL-1) and in-
terleukin-6 (IL-6) in response to stimulation by 
lipopolysaccharide (LPS), which is activated in 
the process of phagocytosis [7, 8]. The increased 
glycosylation may inhibit IL-10 production by 
lymphocytes and macrophages. Additionally, the 
amount of interferon gamma (IFN-g) released by 
T cells and NK cells, and tumor necrosis factor 
(TNF-a) released by T cells and macrophages is 
reduced. The process of glycation also reduces the 
myeloid cells expression of surface major histo-
compatibility complex class I (MHC), which impa-
irs cell-mediated immunity [7, 8]. Hyperglycemia 
reduces the mobilization of polymorphonuclear 
leukocytes, chemotaxis and phagocytic activity. 
Hyperglycemic environment also prevents the 
antibacterial functions of the immune system, 
resulting in inhibition of glucose-6-phosphate 
(G6PD), which in turn stimulates apoptosis of 
leukocytes and reduces the transmigration of le-
ukocytes across the endothelium. In tissues that 
do not consume insulin, hyperglycemic environ-
ment increases the intracellular concentration of 
glucose, which is then metabolized using NADPH 
as a cofactor. The decrease in concentration of 
NADPH prevents the action of molecules that play 
a key role in the mechanisms of antioxidant func-
tions of a cell, which leads to an increase in tissue 
sensitivity to oxidative stress. With respect to the 
mononuclear cells, some studies have shown that 
HbA1c < 8.0% results in the proliferative activity 
of T helper cells (CD4 +) and their response to 
antigens. Glycation of immunoglobulin occurs in 
diabetic patients in proportion with the increase in 
HbA1c, and this may harm the biological function 
of the antibodies (Table 1) [4]. In addition, infec-
tious diseases in patients with DM may result in 
metabolic complications such as hypoglycemia, 
ketoacidosis, and coma. Table 2 shows the effect of 
diabetes on the immune dysfunction in diabetics.
Community and hospital-acquired pneumonia
Community-acquired pneumonia (CAP) is 
one of the most common infections of the lower 
respiratory tract and accounts for 5−12% of 
all LRTI [9]. In Europe, the incidence of com-
munity-acquired pneumonia is estimated to be 
5−12 per 1,000 persons per year. Mortality of 
outpatients with CAP does not exceed 1% of 
hospitalized cases [10]. Pathogens that cause 
CAP are viruses, bacteria and other unusual mi-
crobes. The microbial composition is complex 
and often depends on the geographical area, 
population and seasonal changes. The most 
common CAP pathogens include Streptococcus 
pneumoniae, Mycoplasma pneumoniae, Chla-
mydophila pneumoniae, Legionella pneumophila 
and Haemophilus influenzae. A high percentage 
of CAP cases in adults is due to mixed bacterial 
and atypical pathogens [10, 11]. CAP caused 
by methicillin-resistant Staphylococcus aureus 
(MRSA) is still rare, however, it accounts for an 
increasing number of cases reported in the Uni-
ted States [12, 13]. It is generally accepted that 
MRSA causes more frequently infections of the 
skin and soft tissue than of the respiratory tract. 
CAP caused by Escherichia coli and Klebsiella 
pneumoniae is significantly more frequent in 
patients over 50 years of age [14].
Table 1. Pathophysiological changes resulting from infection in patients with diabetes mellitus 
Diabetes mellitus 
Hyperglycaemia/ un-
controlled diabetes 
Related metabolic 
consequences 
Molecular and  
immunologic events 
Impaired immunological defense 
HbA1c > 8.0%  
Glycosuria 
Glycation, cells 
hypoglycemia, keto-
acidosis, coma 
Inhibit: interleukin 10  
(IL-10) interferon gamma 
(ifn-g) tumor necrosis fac-
tor (TnF-a) lower amounts 
of interleukin-1 (il-1) and 
interleukin-6 (il-6) increase 
in tissue sensitivity to oxi-
dative stress 
Polymorphonuclear dysfunction and reduction of c4 compo-
nent reduces major histocompatibility complex class I (MHc) 
decreased function of the antibodies and T lymphocytes rere-
sponse abnormalities in neutrophil function, such as impaired 
chemotaxis, phagocytes, and bacterial killing 
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Table 2. Pathophysiology of infections associated with diabetes mellitus 
Diabetes mellitus
Decrease T lymphocytes respon-
se, decrease neutrophil function, 
lower secretion of inflammatory 
cytokines, anti-oxidant system 
depression, disorder of humoral 
immunity. 
Hyperglycemia: increased 
virulence of infectious micro-
organisms and apoptosis of 
polymorphonuclear leukocytes . 
Glycosuria.
large number of medical in-
terventions, neuropathy,  
angiopathy
GIT-gastrointestinal tract:  
dysmotility
Hospital-acquired pneumonia (HAP) is lung 
inflammation that occurs at least 48 hours after 
hospital admission. This group of diseases refers 
to pneumonia infections associated with me-
chanical lung ventilation, i.e. it is inflammation 
occurring 48−72 hours of mechanical ventilation 
in patients, as well as pneumonia associated with 
exposure to health care-associated pathogens. The 
incidence in European countries is estimated to 
be 5−15 cases per 1,000 hospitalizations, with 
estimated mortality rate of 30−50%. The most 
common bacteria causing HAP during the first 
four days of hospitalization are: Streptococ-
cus pneumoniae, Haemophilus influenzae, and 
Staphylococcus aureus (methicillin-susceptible), 
and E. coli, K. pneumoniae, Enterobacter, Serratia, 
and Proteus [3, 10]. From the 5th day of hospitali-
zation, there is a predominance of Acinetobacter 
sp, Pseudomonas aeruginosa, E. coli, K. pneumo-
niae, L. pneumophila and Staphylococcus aureus 
(methicillin-resistant MRSA) [10]. The most com-
monly isolated bacteria associated with HAP in 
European countries and the USA is MRSA strain 
Staphylococcus aureus [15].
The Danish researchers attempted to eluci-
date why type 2 diabetes increases the risk of 
death and complications in patients after hospi-
talization for pneumonia, and to evaluate the 
prognostic value of hyperglycemia occurring 
on hospital admission. Their study included 
29,900 patients hospitalized for the first time 
due to pneumonia in the years 1997 to 2004, 
including 2,931 (9.8%) with type 2 diabetes mel-
litus (DM2). The mortality rate among patients 
with DM2 was higher than in patients without 
DM2, and the respective values after 30 days and 
90 days of hospitalization were: 19.9% vs 15.1% 
and 27.0% vs 21.6%, which corresponds to 30 and 
90 days to corrected MRR (mortality rate ratio) of 
1.16 (95% CI 1.07−1.27) and 1.10 (1.02−1.18). 
Patients with pneumonia and DM2 were not at 
risk of pulmonary complications and bacteremia. 
High glucose concentration on admission was 
a predictor of death among patients with diabetes 
and more so among non-diabetic patients: adju-
sted 30-day MRRs for glucose level ≥ 14 mmol/l 
were 1.46 (1.01–2.12) and 1.91 (1.40–2.61), 
respectively. In 60.2% of diabetic and 59.7% 
of other patients with pneumonia at least one 
blood culture was isolated [5]. Streptococcus 
pneumoniae accounted for 51.1% of all episodes 
of bacteremia. Among patients with pneumonia 
with available blood cultures, the adjusted rela-
tive risk (RR) for the occurrence of bacteremia in 
diabetic patients compared to patients without 
diabetes was 1.02 (0.78−1.33). Patients with 
diabetes compared with non-diabetic patients 
had RR similar for pneumococcal bacteremia 
(RR 1.17 [95% CI 0.84–1.62]), a greater risk 
of bacteremia due to gram-positive pathogens 
other than S. pneumoniae (1.69 [1.02–2.80]), 
and a lower risk for gram-negative bacteremia 
(0.72 [0.42–1.23]). The Danish researchers sho-
wed that patients with DM2 have an increased 
risk of death associated with pneumonia hospi-
talization. High glucose levels were related with 
increased mortality in all patients. The results 
showed that glucose level on admission is a very 
important clinical indicator among patients 
with pneumonia [5]. Ehrlich et al. also conduc-
ted a study assessing the risk of pneumonia, 
asthma, chronic obstructive pulmonary disease 
(COPD), pulmonary fibrosis in patients with 
and without diabetes. Retrospective longitudi-
nal cohort study used the electronic records of 
a large health plan in northern California. The 
full cohort study included 77,637 patients with 
diagnosis of diabetes and 1,733,591 patients 
without diabetes. Significantly higher incidence 
of each pulmonary condition, except for lung 
cancer, was observed in patients with diabetes, 
compared with patients without diabetes. The 
prevalence of asthma, COPD, lung fibrosis and 
inflammation was significantly higher in pa-
tients diagnosed with diabetes (Table 3). The 
risk of pneumonia and COPD increased signi-
ficantly with growing concentration of HbA1c 
(hazard ratio [HR] 1.03 [95% CI 1.01−1.04] and 
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Table 3. Analysis of the relationship between diabetes and the occurrence of lung diseases [16]
In diabetic patients adjusted for age, sex, race/ethnicity,  
smoking, BMI, education, alcohol consumption, and number  
of outpatient visits occurring in the 12 months before  
the baseline, health plan members with a diagnosis of diabetes 
HRs and 95% CI for the association between each pulmonary 
condition and diabetes status
Asthma 1.08 (1.03–1.12)
cOPD 1.22 (1.15–1.28)
fibrosis 1.54 (1.31–1.81)
Pneumonia 1.92 (1.84–1.99)
cOPD — chronic obstructive pulmonary disease
1.06 [1.05−1.07] respectively (both p ≤ 0.002), 
but no such associations were observed for asth-
ma and fibrosis. Ehrlich et al. report that in all 
of the analyses (conducted among the full cohort 
or the sub cohort of survey responders, before 
and after adjustment for relevant confounders) 
there was a significant increase in the risk of 
COPD and pneumonia with raising baseline 
HbA1C among patients with diabetes. In patients 
with asthma and fibrosis, associations weren’t 
observed, suggesting that these conditions might 
be related to factors other than glycemic control 
that are associated with diabetes [16].
According to recommendations of the Ame-
rican Diabetes Association (ADA), the Centers for 
Disease Control and Prevention (CDC) and the 
Advisory Committee on Immunization Practices 
(ACIP), anti-pneumococcal and influenza vacci-
nation is advisable for people with DM [4]. The 
Polish Diabetes Association recommends follo-
wing the vaccination schedule, whereas against 
Streptococcus pneumonia, 13-polyvalent vaccine 
is recommended [17]. The use of vaccines helps 
to reduce the number of respiratory infections, 
the frequency and length of hospitalizations, 
deaths caused by respiratory tract infections, 
and medical expenses related to pneumonia [4].
Respiratory tract infections other than pneumonia
Streptococcus pneumoniae and influenza 
virus are the causes of frequent respiratory tract 
infections associated with diabetes mellitus 
(DM) [18]. Natural protection against invasive 
pneumococcal disease is largely conferred by 
anticapsular antibody. It is less clear whether 
they are necessary or they constitute the primary 
mechanism of natural development of resistance 
to pneumococcal infection. Natural pneumococ-
cal immunity may originate through factors other 
than anticapsular antibodies like serotype-speci-
fic polysaccharides. These species antigens are 
found in all or most serotypes that lie beneath 
or are interspersed within the capsular polysac-
charide. These pneumococcal species antigens, 
e.g. pneumococcal surface protein A (PspA) and 
adhesin A (PsaA), are immunogenic early in life, 
and antibodies against them can be elicited by 
mucosal colonization (carriage), otitis media, or 
invasive disease [19]. Nasopharyngeal carriage 
can lead to the development of antibodies against 
specific capsular polysaccharide [20] and surface 
proteins [19−21]. Antibodies effectively opsoni-
ze pneumococci and stimulate macrophages or 
neutrophils to phagocytose [20]. Nam et al. [21] 
studied the function and the titre of protective 
antibodies. Their research aimed at determining 
whether susceptibility to pneumococcal invasion 
in people with diabetes is due to lower titers 
or low availability of antibodies to protective 
polysaccharide capsule and / or protein anti-
gens. Mathews et al. [22] showed that diabetes is 
associated with poor response to anti pneumococ-
cal surface protein (PspA), which was consistent 
with the results obtained by Nam et al. [21]. 
The researchers have shown that the positive 
results of cross-reacting antibodies to PspA in 
diabetic patients were lower compared to patients 
without diabetes. Mathews et al. identified reac-
tion with protein antigen as abnormal in patients 
with diabetes. The response to protein antigens 
was compromised in individuals with diabetes, 
and the T cells play a significant role in respon-
se to protein antigens by activating B cells and 
initiating antibody class switching [22].
DM patients are six times more likely to be 
hospitalized during a flu epidemic compared to 
non-diabetic patients [6]. Diabetes is a common 
co-morbidity risk factor in patients with influenza 
virus infection. Type A and B influenza viruses are 
the common cause of human flu epidemic. The 
Type A virus is divided into subtypes based on the 
antigenic specificity of the hemagglutinin (H) and 
neuraminidase (N). The most common seasonal 
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flu viruses are H1N1 and H3N2 subtypes, someti-
mes H1N2 virus, and to a lesser extent the group B. 
The disease usually resolves spontaneously after 
3 to 7 days, but cough and malaise can persist for 
up to two weeks [23]. Compared to typical seaso-
nal outbreaks, the influenza virus A H1N1 virus 
penetrates deeper into the respiratory system. 
Some patients may rapidly develop progression 
from severe pneumonia to respiratory failure [21]. 
Miller et al. in their study of 43 patients with 
the current HIN1 virus pandemic, revealed that 
the proportion of patients with a flu pandemic 
with comorbid diabetes accounted for 18.6% 
of the cases [24]. Rodríguez-Valero et al. [25] 
studied the differences between early clinical 
symptoms of confirmed cases of H1N1 virus 
infection in hospitalized patients who had been 
tested negative for H1N1 infection. They found 
1,024 patients with acute respiratory symptoms 
who were admitted to the emergency department 
of a general hospital in Mexico from April to De-
cember 2009. The patients had a confirmatory test 
for influenza AH1N1 performed using either re-
al-time or reverse transcriptase polymerase chain 
reaction (RT-PCR). Of the 1,024 patients surveyed, 
H1N1 infection was confirmed in 36%. Diabetes 
was present in 6% of all confirmed hospitalized 
cases of infection. H1N1 infection was often mild 
and affected mostly younger patients. The sud-
den occurrence of symptoms such as pulmonary 
rales, wheezing and the sudden symptom onset 
were more frequent and statistically significant 
in confirmed patients. Influenza-like illness was 
more frequent in confirmed cases (p = 0.049). 
Rodríguez-Valero et al. reported that the presence 
of H1N1 virus was confirmed by RT-PCR. Patients 
with diabetes should be identified to prevent and 
treat potentially severe and fatal cases [25]. Jain 
et al. described the clinical characteristics of pa-
tients in the United States who were hospitalized 
in 2009 due to the H1N1 flu. The study collected 
data from 272 patients treated for at least 24 hours 
because of flu-like symptoms and a positive result 
for the presence of the H1N1 virus on RT-PCR 
assay. Of the 272 patients, 73% had at least one 
of the comorbidities, particularly diabetes occu-
rred in 40 (15%) hospitalized patients [26]. The 
World Health Organization (WHO) recommended 
vaccination against the H1N1 virus, in order to 
minimize the morbidity and mortality caused by 
the viruses. The coverage of anti-flu vaccinations 
in people with DM remains inadequate. The 
recommendation for compulsory immunization 
with anti- flu vaccines is essential because of their 
impact on the reduction of respiratory infections, 
the number and length of hospitalizations and 
the number of deaths related to respiratory tract 
diseases [4]. In patients who were hospitalized 
with seasonal influenza, complications which 
included pneumonia, bacterial coinfection, and 
exacerbation of underlying medical conditions, 
such as congestive heart failure were frequently 
reported [26]. The Polish Diabetes Association 
recommends annual vaccination against influ-
enza virus to children over 6 months of age and 
adults with DM [17]. 
Tuberculosis in patients with diabetes
Approximately 9 million new cases of tu-
berculosis were reported in 2009 worldwide. 
1.7 million people who were diagnosed died 
of tuberculosis infection [27]. Restrepo et al. 
conducted a prospective study on the impact 
of diabetes on clinical outcome of tuberculosis 
(TB). TB patients over the age of 20 from clinics 
in Texas and Mexico have been tested for diabe-
tes. The risk of diabetes among TB patients was 
compared to data from a control adult population. 
The prevalence of diabetes among TB patients 
was 39% in Texas and 36% in Mexico. Diabetes 
contributed to 25% of tuberculosis cases. The au-
thors recommended implementing international 
programs to control diabetes and facilitate the 
prevention of tuberculosis in patients with dia-
betes as well as earlier diagnosis of diabetes [27]. 
People with diabetes are at higher risk of deve-
loping active TB compared to people without 
diabetes [27, 28]. Some studies have shown that 
people with diabetes are more likely to develop 
drug-resistant tuberculosis and treatment failure; 
as a result, mortality is higher in these patients [29]. 
In addition, infection and treatment for tuberculo-
sis (rifampicin activates the metabolism of oral an-
tidiabetic agents) may hinder glycemic control [30].
It has been suggested that DM causes a re-
duction in the immune response (reduced chemo-
taxis, phagocytosis and antigen presentation in 
response to Mycobacterium tuberculosis infection 
and changes in the function and proliferation 
of T lymphocytes), thus facilitates infection 
and progression of the symptoms of the disease 
[27−29]. Patients with type 2 diabetes are at in-
creased risk of developing tuberculosis, which 
can be attributed to the mononuclear phagocyte 
functional drawbacks, which play a key role in 
defending against infection with Mycobacterium 
tuberculosis. The cause of increased susceptibi-
lity to tuberculosis in patients with DM2 may be 
related to dysfunctional immunity [31]. Immune 
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Table 4. Immune changes in patients with diabetes increasing incidence of infection with Mycobacterium tuberculosis 
Molecular and immunologic events Interaction between m. Tuberculosis  
and the host phagocyte in DM patients 
Impaired immunological defense 
impaired T-cell proliferation reduced T-helper 
(Th)-associated chemokine receptors  
and cytokines 
Monocytes migrate to sites in tissues  
infected by M. tuberculosis, which contribute 
to the local response 
Decrease t lymphocytes response and reduced 
chemotaxis and antigen presentation
in response to Mycobacterium tuberculosis
Reduced ifn-g production at the onset  
of disease
Opsonization of M. tuberculosis by serum 
components, with c3b,  ic3b and natural 
antibodies to mycobacteria 
Reduced association of M. tuberculosis  
with monocytes in patients with diabetes
Monocytes have a reduced activity binding 
and phagocytosis of M. tuberculosis
Defective opsonization such as c3b/ic3b, 
and/or natural igG and/or complement recep-
tors cRs (cR1, cR3) and receptors fcgRs  
on the monocytes
Binding of opsonins to complement  
receptors (cR1 and cR3) or, fcg receptors on 
the monocyte, which is followed  
by phagocytosis
dysfunction in infected diabetes patients revealed 
reduced T-helper (Th)-associated chemokine re-
ceptors and cytokines, impaired T-cell prolifera-
tion and reduced IFN-g production at the onset of 
disease [7]. T cells, by the release of interferon-g 
(IFN-g), induce autophagy, phagosomal matura-
tion, the production of antimicrobial peptides 
and antimicrobial activity against Mycobacterium 
tuberculosis in macrophages [32]. Mononuclear 
phagocytes (monocytes and macrophages) play 
an important role in the immunopathogenesis of 
TB [33]. In macrophages infected with Mycobac-
terium tuberculosis, the pathogen accumulates in 
phagocytic vesicles or early endosomes, which 
fail to localize lysosomes as identified with the 
lysosomal marker [32]. Monocytes also migrate 
to sites in tissues infected with M. tuberculosis, 
which contributes to the local response. Given 
the importance of monocytes in the biology of 
M. tuberculosis, it is probable that the functional 
changes in the cells of patients with DM2 contri-
bute to increased susceptibility to tuberculosis 
or in TB-infected individuals to infection [34]. 
In patients with DM2 who are yet to be treated, 
monocytes have a reduced activity (binding and 
phagocytosis activity towards M. tuberculosis) of 
M. tuberculosis compared to non-diabetic mono-
cytes [35], suggesting defective serum opsoniza-
tion routes (such as C3b/iC3b, and/or natural IgG) 
and/or complement receptors (CRs) and receptors 
FcgRs monocytes. Further experiments with the 
M. tuberculosis inactivated serum that opsonized, 
suggest that the defect is linked to the termolabile 
element. DM2 patients may have CRs changes 
that adversely affect the binding and phagocy-
tosis by monocytes to M. tuberculosis: the defect 
may be associated with monocyte receptor (CR1, 
CR3) and/or their ligands in serum (complement 
protein C3b and its breakdown product iC3b). Re-
strepo et al. demonstrated that human monocytes 
in DM2 patients have functional defects in the 
process of phagocytosis of M. tuberculosis, opso-
nization with serum, lanes intermediate and/or 
receptors CRs and FcgRs, which is correlated 
with chronic hyperglycemia. This disadvantage 
is independent of host opsonization with serum 
or plasma, and is not associated with reduced 
expression of CR3, R-I and-II-III, or upregulation 
of inhibitory receptor CD32B. Higher susceptibi-
lity of DM patients to such pathogens as M. tu-
berculosis is associated with activation of effector 
mechanisms for killing bacteria. It is probable 
that the defect is one of the factors involved in 
the higher sensitivity in patients with DM2 to 
pathogens such as M. tuberculosis (Table 4). In 
summary, these results indicate that the reduction 
in phagocytosis by CRs and FcgRs is at least partly 
linked to the drawbacks associated with the same 
monocytes in DM2. Further studies are needed to 
evaluate the relationship between the decrease 
in phagocytosis by monocytes in DM2 and its 
activation [35, 36].
Respiratory mycosis
The analysis of clinical epidemiology of 
fungal infections in diabetic patients has shown 
that diabetes was associated with an increased 
incidence of fungal infections. The study inc-
luded 221 patients with DM2 over 10 years, 
and it found that infections and pneumonia 
accounted for 22% of all deaths. It has been es-
timated that 50–75% of cases of fungal infections 
in diabetic patients are caused by Mucorales, 
while acidosis is a predisposing factor. The 
second microorganism responsible for onycho-
mycosis in diabetic patients is Aspergillus [37]. 
Aspergillus is a ubiquitous fungus that causes 
many clinical syndromes, including: invasive 
pulmonary aspergillosis (IPA), chronic necrotic 
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form of aspergillosis, aspergillus mycetoma and 
allergic bronchopulmonary aspergillosis. IPA is 
a severe and often fatal disease that occurs in 
immunocompromised patients, and allergic bron-
chopulmonary aspergillosis is a hypersensitivity 
reaction to Aspergillus antigens, which mainly 
affects patients with asthma. Although diabetes 
predisposes individuals to the development of 
fungal infections, aspergillosis is relatively rare 
in these patients [38, 39].
Mucormycosis can be categorized according 
to the site of infection, including nasal-cerebral, 
pulmonary, gastrointestinal, cutaneous and dis-
seminated. In diabetic patients nasal-cerebral or 
pulmonary embolism are the most common forms 
of mucormycosis, which can occur after a lung 
infection [40, 41]. Pathogens associated with this 
disease include the Zygomycetes fungi (Phycomy-
cetes), the most common family of Mucoraceae, 
including Rhizopus, Absidia and Mucor. Though 
acidosis is a predisposing factor, it only occurs in 
about 50% of diabetic patients with concomitant 
fungal infection [42]. These infections are caused 
mainly by the fungi of the genus Rhizopus. Rhi-
zopus fungi cause inflammation of the middle 
ear, nasal cavity, paranasal sinuses, lungs and 
meniges. Hypotheses attempting to explain the 
increased incidence of mucormycosis include: 
increased availability of iron to the pathogen at 
lower pH values, lack of inhibitory activity in the 
serum of Rhizopus species at lower pH values and 
the presence of pulmonary macrophages in pa-
tients with DM, which reduced the ability to pre-
vent germination of Rhizopus species [39, 41, 42]. 
The pathogenesis of the disease probably starts 
with the inhalation of the fungus to the parana-
sal sinuses. Initial symptoms may include fever, 
headache, and facial pain or swelling, pain in the 
eye or periosteum orbital edema or blocked nose. 
There is soft tissue swelling and bloody nasal 
discharge from the external nasal cannula. Infec-
tion can cause slight fever and impaired conscio-
usness. The black scabs in the mucosa of the nose 
and palate, which occur in approximately 40% 
of patients, are due to tissue necrosis following 
vascular invasion of the fungus. Invasion is fast 
and can lead to exophthalmos, ophthalmoplegia, 
and blindness that are caused by the seizure of the 
orbit. Patients may also experience cranial nerve 
palsy caused by the seizure of the cavernous si-
nus or massive stroke caused by occlusion of the 
carotid artery. Early diagnosis and treatment of 
the condition in patients with diabetes mellitus 
is important to reduce the invasion of the fungus, 
and associated morbidity and mortality [42, 43].
Summary 
Inadequate blood glucose control in diabetes 
predisposes patients to pneumococcal pneumo-
nia, but the degree of hyperglycemia in diabetes 
is not associated with an increase in disease se-
verity. In contrast to non-diabetic patients with 
pneumococcal pneumonia, hyperglycemia is 
a marker for severe disease and increased mortali-
ty, probably because of mass release of proinflam-
matory cytokines and glucocorticoids during the 
infection process. Diabetic lung infection causes 
a change in the entire lung immune system of the 
host organism, with associated changes in the 
local and ciliated epithelial dysfunction and its 
mobility. The relationship between diabetes and 
pulmonary tuberculosis is linked to loss of func-
tion of the body’s defense and antigen-presenting 
ability, which promotes the formation of clinical 
and radiological changes in patients with dia-
betes mellitus. Thus, worsening of tuberculosis 
appears to be important for the immune system 
and the severity of hyperglycemia. Particularly 
noteworthy is the incidence of diabetes in the case 
of influenza virus or flu-like infection. Complica-
tions such as pneumonia and even death, occur 
more often than in the general population. There 
is the empirical antiviral therapy in hospitalized 
patients with suspected H1N1 flu or pneumo-
nia in patients at risk group like persons with 
diabetes. Some researchers relate the presence 
of elevated glucose levels in diabetic patients 
with increased development of infection and 
the resulting inability to control the infection. 
Although the optimal control of blood glucose 
levels helps to prevent the occurrence of life-thre-
atening infections associated with diabetes, the 
increased susceptibility to infections is attributed 
to defective functioning of cellular and humoral 
immunity. In addition, an aging immune system 
is associated with an increased risk of bacterial, 
mycobacterial, fungal, and viral infections.
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